Skip to main content
. 2016 Oct 18;6:35615. doi: 10.1038/srep35615

Table 4. Relationships between Polymorphisms of SLC19A1, FPGS, or GGH and adverse events stratified by genotype.

    genotype AE(−) group AE (+) group P value
SLC19A1 rs1051266 80G > A GG/AG/AA GG/AG/AA p = 0.139
68/93/27 26/37/20
FPGS rs10106 1994A > G AA/AG/GG AA/AG/GG p = 0.952
91/78/19 39/37/7
rs1054774 11694T > A TT/AT/AA TT/AT/AA p = 0.289
73/89/26 40/38/10
rs1544105 2572C > T CC/CT/TT CC/CT/TT p = 0.327
93/80/15 35/40/8
GGH rs719235 452C > T CC/CT/TT CC/CT/TT p = 0.688
151/32/5 65/15/3
rs1800909 −401C > T CC/CT/TT CC/CT/TT p = 0.477
7/22/159 5/14/64
rs3758149 −354G > T GG/GT/TT GG/GT/TT p = 0.125
121/61/6 56/23/4
rs11545078 16T > C TT/CT/CC TT/CT/CC p = 0.582
163/25/0 70/12/1
rs12681874 14269G > A GG/AG/AA GG/AG/AA p = 0.174
61/92/39 20/42/21

p values for comparisons between the AE (+) and AE (−) groups were evaluated by the Kruskal-Wallis test.

SLC19A1: reduced folate carrier 1, FPGS: folylpolyglutamyl synthase, GGH: gamma-glutamyl hydrolase.